These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ; Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822 [TBL] [Abstract][Full Text] [Related]
12. The role of treprostinil in the management of pulmonary hypertension. Skoro-Sajer N; Lang I Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755 [TBL] [Abstract][Full Text] [Related]
13. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098 [TBL] [Abstract][Full Text] [Related]
14. Treprostinil for the treatment of pulmonary arterial hypertension. Torres F; Rubin LJ Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441 [TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial. Grünig E; Benjamin N; Lange TJ; Krueger U; Klose H; Neurohr C; Wilkens H; Halank M; Seyfarth HJ; Held M; Traube A; Pernow M; Grover ER; Egenlauf B; Gerhardt F; Viethen T; Rosenkranz S Respiration; 2016; 92(6):362-370. PubMed ID: 27784026 [TBL] [Abstract][Full Text] [Related]
17. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071 [TBL] [Abstract][Full Text] [Related]
19. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684 [TBL] [Abstract][Full Text] [Related]
20. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]